| |
Improve clinical outcomes by creating more flexible, patient-focused protocols that enhance enrollment and boost patient engagement with IQVIA Patient Centricity in Design. Get the fact sheet. 
|
|
| By Kevin Dunleavy,Fraiser Kansteiner The White House has revealed significantly reduced prices for 10 prescription drugs affected by the first wave of Medicare negotiations mandated by the Inflation Reduction Act, the Biden administration initiative which includes several measures designed to lower the cost of healthcare in the U.S. |
|
|
|
By Nick Paul Taylor Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time. |
By Kevin Dunleavy Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. |
By Nick Paul Taylor Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the Big Pharma as a rival to Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune disease. |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
By Zoey Becker The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study. |
By Kevin Dunleavy With Gilead on the verge of an FDA decision for its liver disease drug seladelpar, the company has paid Johnson & Johnson $320 million to exit an 18-year-old licensing agreement on the compound. The buyout removes Gilead’s obligation to pay an 8% royalty on sales of seladelpar. |
By Conor Hale Last month, CEO Kevin Lobo said Stryker planned to pursue multiple M&A deals this year. It hasn’t taken long to start making good on that promise. |
By Andrea Park To brew up the latest iteration of its ongoing initiative to provide deeper education around chronic skin conditions, AbbVie sought help from a onetime teenage witch. |
By Darren Incorvaia The muscle protein titin has long been the titan of the molecular world. Built of more than 34,000 amino acids and weighing in at a hefty 3.7 megadaltons, titin has long been considered the largest protein in the world—until now. |
By Fraiser Kansteiner Facing a unique set of challenges and staring down multiple new technologies and modalities, CDMOs must work to recalibrate their leadership requirements if they hope to stay on the cutting edge, executive search advisory firm WittKieffer said in a new report. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," we’re discussing the challenges and opportunities for telehealth, given some notable setbacks for the industry in recent months. |
|
|---|
|
|
|
Sept. 25 - 26, 2024 |San Diego, CA Establish a strategic and tactical launch plan for medical affairs teams that align with the organization’s overall business objectives. Complimentry Passes Available! Learn More. .png)
|
|
Whitepaper The pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. Download this playbook to discover the future of BioPharma financial analysis. Sponsored by: Visible Alpha, now a part of S&P Global Market Intelligence |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
